Advertisement

Topics

Bourne Partners Advises Accelovance on Sale to Linical

08:00 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Accelovance, Inc. (“Accelovance”), a global contract research organization (CRO) focused on oncology, vaccines and general medicine, has been acquired by Linical, a leading, Asia-based CRO providing services in the areas of ...

Other Sources for this Article

Bourne Partners
Lindsey Stevens, 704-552-8407
lstevens@bourne-partners.com

NEXT ARTICLE

More From BioPortfolio on "Bourne Partners Advises Accelovance on Sale to Linical"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...